Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This
occurs as a result of destructive changes in an area of the brain responsible for making
dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped
posture, and a shuffling-type walk (gait).
In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the
treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that
are associated with the symptoms of Parkinson's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)